FORUM ON EMERGING INFECTIONS

JOSHUA LEDERBERG1(Chair),

Sackler Foundation Scholar, The Rockefeller University, New York

VINCENT I. AHONKHAI, Vice President and Director,

Anti-Infectives and Biologicals, SmithKline Beecham Corporation, Collegeville, Pennsylvania

STEVEN J. BRICKNER, Manager of Medicinal Chemistry,

Central Research Division, Pfizer, Inc., Groton, Connecticut

GAIL H. CASSELL,2

Vice President for Infectious Diseases Research, Drug Discovery Research, and Clinical Investigation, Eli Lilly & Company, Indianapolis

GORDON H. DEFRIESE,2 Director and Professor of Social Medicine,

Epidemiology, Health Policy, and Administration, Sheps Center for Health Services Research, University of North Carolina, Chapel Hill

NANCY CARTER FOSTER,3 Director,

Program for Emerging Infections and HIV/AIDS, Department of State, Washington, D.C.

RENU GUPTA, Senior Medical Director,

Infectious Diseases, Bristol-Myers Squibb Company, Princeton, New Jersey

MARGARET A. HAMBURG,2 Assistant Secretary for Planning and Evaluation,

Department of Health and Human Services, Washington, D.C.

DIETER HINZEN, Professor and Head of Preclinical Research,

F. HoffmannLaRoche, A.G., Basel, Switzerland

JAMES M. HUGHES,3 Assistant Surgeon General, and Director,

National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta

J. STANLEY HULL, Vice President,

Global Commercial Development, Glaxo Wellcome, Research Triangle Park, North Carolina

SAMUEL L. KATZ,2 Chairman of the Board,

Burroughs Wellcome Fund, and Wilburt C. Davison Professor, Department of Pediatrics, Duke University Medical Center

KENNETH W. KIZER,3 Under Secretary for Health,

Veterans Health Administration, Department of Veterans Affairs, Washington, D.C.

WILLIAM KOHLBRENNER, Director,

Antiviral Research, Abbott Laboratories, Abbott Park, Illinois

JOHN R. LaMONTAGNE,3 Deputy Director,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

CARLOS LOPEZ, Executive Director,

Infectious Disease Research, Eli Lilly Research Laboratories, Indianapolis

1  

Member, Institute of Medicine and National Academy of Sciences.

2  

Member, Institute of Medicine.

3  

Ex-officio member.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement